Company news

Ocugen, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America

April 17, 2022

Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)

April 11, 2022

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

March 31, 2022

Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors

March 22, 2022

Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance

March 20, 2022

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 17, 2022

Ocugen, Inc. to Present at the 34th Annual ROTH Conference

March 8, 2022

Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request

March 3, 2022

Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results

February 24, 2022

Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock

February 21, 2022

Ocugen to Host Conference Call on Friday, February 25 at 8: 30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

February 17, 2022

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

February 17, 2022

Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options

February 14, 2022

Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada

January 26, 2022

Ocugen Inc. Announces Nirdosh Jagota, Ph.D. as Senior Vice President, Regulatory Affairs, Compliance & Safety

January 23, 2022

Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 20, 2022

COVAXIN™ (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2

January 11, 2022

COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

January 7, 2022

Ocugen, Inc. to Present at Upcoming H.C. Wainwright Bioconnect Conference

January 5, 2022

Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS

December 29, 2021

Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 19, 2021

New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination

December 14, 2021

Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

December 8, 2021

Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

November 25, 2021

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 17, 2021

Ocugen Provides Business Update and Third Quarter 2021 Financial Results

November 8, 2021

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate OCU400 (AAV-NR2E3) to Treat Inherited Retinal Degeneration

November 7, 2021

Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years

November 4, 2021

Ocugen to Host Conference Call on Tuesday, November 9 at 8: 30 a.m. ET to Discuss Third Quarter 2021 Financial Results and Provide Business Update

November 1, 2021

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

October 26, 2021

Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference

October 18, 2021

Ocugen Provides Business Update and Second Quarter 2021 Financial Results

August 5, 2021

Ocugen to Host Conference Call on Friday, August 6 at 8: 30 a.m. ET to Discuss Second Quarter 2021 Financial Results and Provide Business Update

July 29, 2021

Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN™

July 14, 2021

Ocugen, Inc. Announces Ken Inchausti as Head, Investor Relations & Communications

June 20, 2021

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 17, 2021

Ocugen Inc. Set to Join Russell 3000® Index

June 15, 2021

Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™

June 14, 2021

Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial

June 9, 2021

Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada

June 2, 2021

Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™

May 25, 2021

Ocugen Provides Business Update and First Quarter 2021 Financial Results

May 6, 2021

Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2

May 2, 2021

Ocugen Inc. Announces Closing of $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

April 27, 2021

Ocugen Inc. Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

April 22, 2021

Ocugen Inc. Announces John Paul Gabriel as Senior Vice President, Manufacturing and Supply Chain

April 13, 2021

Ocugen Provides Business Update and Full Year 2020 Financial Results

March 17, 2021

Ocugen to Host Conference Call on Thursday, March 18 at 8: 30 a.m. ET to Discuss 2020 Financial Results and Provide a Business Update

March 11, 2021

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis

February 22, 2021

Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock

February 9, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 75 decks. Every deck is listed under its year.